Overview

Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes

Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of Dextenza intracanalicular insert in patients with ocular graft-versus-host disease (GVHD).
Phase:
Phase 4
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Collaborator:
Ocular Therapeutix, Inc.
Treatments:
Dexamethasone